New updates have been reported about Evergreen Nephrology.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Evergreen Nephrology reported standout 2024 results in the Center for Medicare & Medicaid Innovation Kidney Care Choices program, generating more than $40 million in total Medicare savings and ranking second nationally among Kidney Contracting Entities in net savings. The company’s value-based kidney care model, deployed with nephrologist partners across the U.S., produced approximately $225 in savings per patient per month while improving outcomes for individuals with advanced chronic kidney disease.
Evergreen and its partner groups earned over $35 million in performance payments tied to care quality and achieved a 2.3% net shared savings rate, with total program payouts rising 24% year over year, signaling both scale expansion and sustained performance. Clinically, Evergreen reports a 58% optimal start rate for kidney replacement therapy, delayed progression to kidney failure in 35% of a tracked CKD 4 cohort, and a 25% higher transplant access rate than the national average, reinforcing the business case for early intervention and coordinated care.
Chief Executive Officer Heather Trafton said the results demonstrate how data, care teams, and infrastructure enable nephrologists to better manage complex kidney disease while lowering total cost of care and building a more sustainable economic model. Evergreen’s performance strengthens its position as a preferred partner for nephrology practices and payors in risk-based arrangements and underscores the scalability of its approach across its 24-state network of more than 1,000 providers.
The strong KCC outcomes may support Evergreen’s leverage in future contracting with Medicare and commercial payors and could accelerate physician alignment as practices seek operational support for value-based kidney care. For stakeholders, the 2024 metrics highlight Evergreen’s ability to translate quality improvement into predictable shared savings and bonus income, positioning the company to benefit as regulators and insurers continue shifting kidney care toward advanced risk-bearing models.